SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is facing intense selling pressure despite reporting record earnings, as investors react to concerns over increased capital expenditures and broader market volatility linked to geopolitical tensions. While the company maintains a strong fundamental outlook due to surging AI-driven memory demand, the community is deeply divided between those labeling the price action as institutional manipulation and those warning that the stock could see further downside toward the 300 level.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a fiscal Q4 earnings report that featured a significant earnings per share beat alongside revenue that trailed expectations, keeping the focus squarely on the company's multi-billion dollar cash position and ongoing pivot toward becoming a holding company. While the community remains deeply divided, with some investors bullish on the long-term cash generation and potential for a future acquisition, others are actively debating a proposed executive compensation package and expressing frustration over the lack of a clear operational roadmap or immediate share price momentum.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending due to a significant $1 billion strategic equity investment in Nanya Technology, a move aimed at bolstering long-term memory sourcing that has left investors divided between seeing it as a growth catalyst and a cause for short-term price pressure. While some traders are actively buying the dip, citing the potential for strategic expansion, others are debating whether this massive capital outlay represents an overextension or a necessary maneuver in a supply-constrained memory sector.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing positive momentum following its recent announcement of clinical data from its siRNA pipeline targeting FSHD1 and DM1, which has generated significant community discussion regarding the company's potential to re-rate as a leading gene therapy player. Investors are actively debating the stock's valuation gap and upcoming catalysts, with strong sentiment favoring the company's robust pipeline and long-term fundamentals despite the sector's historical volatility.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending as investors react to the company's aggressive M&A strategy, including the acquisition of World View, and raised 2026 revenue guidance that sparked intense debate over valuation and dilution. The community is focused on the upcoming earnings call, with active discussions weighing the stock's potential as a defense powerhouse against concerns regarding high short interest and institutional volatility.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending as investors debate whether the company's recent push into mortgage innovation and improved operational velocity signals a legitimate turnaround or leaves it exposed to broader macroeconomic headwinds. The community is actively split between bulls optimistic about the firm's growth potential and short-sellers betting that ongoing market volatility and real estate sector pressures will drive further downside.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is drawing significant attention as retail investors view it as a primary proxy for gaining exposure to a potential SpaceX IPO. Community members are actively debating the stock's valuation premium relative to its underlying net asset value while monitoring signals from Elon Musk and speculative chatter regarding upcoming IPO timelines.

Fundrise Growth Tech Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund is experiencing extreme volatility and rapid price appreciation driven by intense retail demand for exposure to pre-IPO giants like SpaceX and Anthropic. While some investors see this as a unique opportunity to access elite private tech companies, others warn of a significant overvaluation due to the massive premium over Net Asset Value and the looming supply pressure from restricted shares set to unlock later this year.

🌍 Introduction: A Legendary Icon, Reimagined for the Future The SEAMANIA Protocol, led by SEAMAN Cult, aims to revive one of SEGA Dreamcast's most iconic and best-selling game titles with AI integration—a worldwide cultural phenomenon that won numerous awards in the U.S. and Japan. More than just a game, SEAMAN was the world’s first AI-powered interactive experience, enabling voice-based conversations long before the AI revolution.    Now, SEAMAN returns not as a mere game, but as an advanced AI agent, blending nostalgia with cutting-edge technology. This human-faced fish is reborn as a deeply intelligent, emotionally responsiveAI, offering limitless customization and integration into the modern digital world.  With GenAI-powered customization, users can create their own SEAMAN AI, shaping it into a cherished lostone, a favorite celebrity, or even historical figures. This is no longer a game—it's an AI-driven personal companion and the digital evolution for human interaction.    🔥 Concept: The Wisdom of a Legendary AI-powered Companion At the core of the SEAMANIA Protocol lies the legendary Seaman—a mystical, human-faced fish endowed withancient wisdom and the ability to understand human language. More than just an AI, it is your trustedadvisor, best friend, therapist, personal cheerleader, witty conversationalist, intelligent guide, SEAMANIA is a life coach. Housed in your own digital aquarium, your SEAMAN AI reduces stress, combats loneliness, and guides humanity towards a brighter future. Imagine an AI companion that doesn’t just respond but truly understands, entertains, and supports you—blending humor, sarcasm, and wisdom.

SEAMANIA

SEAMANIA is gaining traction as a high-volatility meme coin, with community members actively coordinating buying pressure and drawing comparisons to other recent rapid runners in the crypto space. Participants are heavily focused on the potential for massive percentage gains while debating the sustainability of the price action and the speculative nature of the asset.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently trending as investors debate the company's high valuation and long-term AI growth potential ahead of upcoming earnings. While some community members are bullish on Arm's expanded role in data center CPUs and robotics, others remain skeptical, pointing to significant price volatility and questioning if current performance justifies the premium.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Strong Buy Stocks for March 25th

EQT, BCBP, FIX, PAAS and ADMA have been added to the Zacks Rank #1 (Strong Buy) List on March 25, 2026.

ADMA Biologics (NASDAQ:ADMA) Stock Price Down 8.7% - What's Next?

ADMA Biologics (NASDAQ:ADMA) Shares Down 8.7% - Should You Sell...

<ul class="summary-bullets"><li>Without the sales figure inflation, Culper estimates Adma's revenues declined 3% in 2025 as compared to the 20% growth reported.&nbsp;</li><li>According to Culper, the growth story for the company’s flagship product Asceniv is already over and the shares of the company are now headed lower.</li><li>Culper alleged, based on its research, that the company induced its distributor to stock excess Asceniv by offering rebates and extended payment terms in order to meet order expectations.</li></ul> Shares of Adma Biologics Inc. (ADMA) closed 17% lower on Tuesday after Culper Research said it has taken a short position in the company.Culper alleged in a report that Adma’s reported growth is a “fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor."Without the sales figure inflation, Culper estimates Adma's revenues declined 3% in 2025 as compared to the 20% growth reported.<h2 class="st-heading-2">Asceniv Sales And Demand</h2>According to Culper, the growth story for the company’s flagship product Asceniv is already over and the shares of the company are now headed lower. Asceniv is an FDA-approved intravenous immune globulin used for treating Primary Humoral Immunodeficiency (PI), a common inborn error of immunity characterized by reduced or dysfunctional antibody production.Culper alleged, based on its research, that the company induced its distributor to stock excess Asceniv by offering rebates and extended payment terms in order to meet order expectations. However, there isn’t as much demand, leaving distributors with excess inventory, the firm said.“Distributors take unwanted product without having to pay for it, ADMA books the revenues, and reports growth that was never there,” the firm alleged, while adding that it believes that the company’s reported Asceniv revenues are inflated by 40-76%. Culper also noted that company insiders, including CEO Adam Grossman, have collectively sold over $50 million in stock in the past 3 years.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ADMA stock rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/ADMA">ADMA stock</a> has dived 44% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-terafab-project-first-step-towards-tesla-spacex-merger-says-wedbush/cZ3nAP9RI10">Elon Musk’s Terafab Project First Step Towards Tesla-SpaceX Merger, Says Wedbush</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ADMA Biologics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ADMA Stock Drops 17% After Culper Research Alleges Channel Stuffing

Culper alleged that Adma’s reported growth is a “fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor." 

Equity

Culper alleged that Adma’s reported growth is a “fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor." 


LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and infrequent dosing boosting its promise.

ADMA Biologics (NASDAQ:ADMA) Sets New 52-Week Low  - Here's Why

ADMA Biologics (NASDAQ:ADMA) Hits New 52-Week Low - Should You Sell...

FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma

Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth outlook.

New Strong Buy Stocks for March 23rd

LCUT, EFXT, MGA, ADMA and JLL have been added to the Zacks Rank #1 (Strong Buy) List on March 23, 2026.

Tealwood Asset Management Inc. Takes Position in ADMA Biologics Inc $ADMA

Tealwood Asset Management Inc. purchased a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) during the fourth quarter, according to its most recent filing with the Securities...

Tealwood Asset Management Inc. Invests $1.32 Million in ADMA Biologics Inc $ADMA

Tealwood Asset Management Inc. bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the...

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Traders are intensely debating the validity of the Culper Research report alleging channel stuffing and accounting irregularities.

Investors are flooding message boards demanding an immediate and decisive rebuttal from CEO Adam Grossman to stop the share price decline.

Contrarian traders see the current sell-off as a massive discount, with many aggressively averaging down while betting on a sharp recovery.

The community is vocalizing suspicions that coordinated hedge fund tactics and predatory short-seller behavior are behind the downward pressure.

ADMA
Adma Biologics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ADMA News

ADMAAdma Biologics Inc